Alnylam Pharmaceuticals | ALNY - Ebitda

Stock Price
353.76
Daily Change
1.96 0.56%
Monthly
-11.08%
Yearly
28.03%
Q1 Forecast
327.65

Alnylam Pharmaceuticals reported $381.78M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Agios Pharmaceuticals USD -125.8M 20.45M Jun/2025
Alnylam Pharmaceuticals USD 381.78M 362.95M Sep/2025
Amgen USD 5.91B 2.31B Sep/2025
Arrowhead Research USD 64.2M 223.53M Sep/2025
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Incyte USD 581.52M 358.87M Jun/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
Moderna USD -208M 552M Sep/2025
Neurocrine Biosciences USD 246.7M 93.8M Sep/2025
Novartis USD 5.84B 235M Sep/2025
PTC Therapeutics USD -33.11M 1B Jun/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Sanofi EUR 5.66B 3.77B Sep/2025
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
Takeda JPY 448.13B 173.98B Dec/2025
Tectonic Therapeutic USD -13.48M 5.73M Dec/2024
Ultragenyx Pharmaceutical USD -91.34M 35.09M Jun/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025
Xencor USD -30.52M 6.39M Jun/2025